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Abstract
Background—Haemophilia care is commonly provided via multidisciplinary specialized 
management. To date, there has been no systematic assessment of the impact of haemophilia care 
delivery models on patient-important outcomes.
Objective—To conduct a systematic review of published studies assessing the effects of the 
integrated care model for persons with haemophilia (PWH).
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Search methods—We searched MEDLINE, EMBASE and CINAHL up to April 22, 2015, 
contacted experts in the field, and reviewed reference lists.
Selection criteria—Randomized and non-randomized studies of PWH or carriers, focusing 
mainly on the assessment of care models on delivery.
Data collection and analysis—Two investigators independently screened title, abstract, and 
full text of retrieved articles for inclusion. Risk of bias and overall quality of evidence was 
assessed using Cochrane’s ACROBAT-NRSI tool and GRADE respectively. Relative risks, mean 
differences, proportions, and means and their variability were calculated as appropriate.
Results—27 non-randomized studies were included: eight comparative and 19 non-comparative 
studies. We found low- to very low-quality evidence that in comparison to other models of care, 
integrated care may reduce mortality, hospitalizations and emergency room visits, may lead to 
fewer missed days of school and work, and may increase knowledge seeking.
Conclusion—Our comprehensive review found low- to very low-quality evidence from a limited 
number of non-randomized studies assessing the impact of haemophilia care models on some 
patient-important outcomes. While the available evidence suggests that adoption of the integrated 
care model may provide benefit to PWH, further high-quality research in the field is needed.
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Introduction
Haemophilia care is complex, often requiring health management beyond the prevention and 
treatment of bleeding. Ad hoc trained haematologists and nurses have the knowledge and 
experience to address a wide range of haemophilia-specific needs [1,2]. Musculoskeletal 
experts, such as physical therapists, can help manage recovery from bleeding into joints and 
prevent chronic joint damage. Psychosocial support can be delivered by social workers and 
psychologists, as persons with haemophilia (PWH) often experience social stigma, 
vocational challenges and decreased quality of life [3]. Infectious disease specialists and 
gastroenterologists have been required to manage viral infections, such as HIV and hepatitis 
C.
As a result, care for PWH is often multidisciplinary and specialized. This model of care can 
be defined as ‘integrated care’, and is the most largely represented of the four principle care 
models for PWH available for adoption in the Western world. The integrated care model is 
usually delivered by Comprehensive Care Centers (‘comprehensive care’ is used as an 
alternative definition for integrated care), which provide all components of care (including 
supervision of home-based treatment) via coordinated and geographically co-located 
multidisciplinary teams. Comprehensive Care Centers coordinate care, secure and 
administer funding, provide technical assistance, organize professional education and 
training, and engage in data collection and analysis.
There are three alternative models of care. In a specialist-based care model, a haematologist, 
who may or may not have specialized training in haemophilia, provides care in a non-
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specialized centre, such as a hospital or medical office. Care delivered by a non-specialist in 
a non-specialist setting takes the form of a family physician delivering care in their practice, 
or an emergency room physician delivering care in an emergency room setting. The ‘no 
care’ model, with a complete absence of dedicated care, does not appear to be operating in 
the Western world, but exists in other areas of the world where PWH do not have access to 
care due to profound resource constraints [4,5].
While the integrated care model has been strongly supported by physician and patient 
organizations since its introduction in the United Kingdom in the late 1940s [6–9] and 
increased uptake in the 1960s and 1970s, and is currently widely accepted as the ‘de facto’ 
standard of care, there have been no attempts to systematically assess the evidence 
comparing the different care models for PWH. The aim of this paper is to report the results 
of a systematic review of the literature to assess the impact of haemophilia care models on 
patient-important outcomes.
Materials and methods
This systematic review was performed according to methods in the Cochrane Collaboration 
Handbook [10] and reported according to the PRISMA statement [11], and was used to 
provide the evidence base for a guideline addressing the choice of care models for the 
management of haemophilia [12].
Inclusion and exclusion criteria
Inclusion and exclusion criteria were defined a priori. Included articles had to report on 
PWH or carriers, and had to focus on haemophilia care models, defined as: integrated care; 
care delivered by a specialist in a non-specialist setting; care delivered by a non-specialist in 
a non-specialized setting; and no care. Included articles had to report on a health care model 
(or models) of interest, or report on a health care model of interest and an add-on care 
delivery option (such as home care). Since it was anticipated that there would be few studies 
comparing different models of care, randomized and non-randomized studies were included. 
Non-randomized studies could compare models or describe a single model of care.
Outcomes
Articles had to report on at least one of the following outcomes: mortality, missed days of 
school or work, emergency room visits, length of in-patient stay, quality of life, joint damage 
or disease (and other measures of functional status), educational attainment, patient 
adherence, and patient knowledge. These outcomes were identified through a survey given 
to a panel of clinicians, programme managers, researchers, patients with haemophilia and 
caregivers as critical or important to patients [12].
Search strategies
We searched OVID MEDLINE, OVID MEDLINE In-Process and Other Non-Indexed 
Citations, OVID EMBASE, and EBSCO Cumulative Index to Nursing & Allied Health 
Literature (CINAHL) databases up to April 22, 2015. We also contacted clinical experts in 
the field and used snowballing through references to identify studies. The search strategies 
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consisted of MeSH headings, keywords and text words related to haemophilia, models of 
care and health services, and were not restricted by language or study design. Complete 
search strategies are provided in Appendix S1.
Study selection and data extraction
Two investigators (SM and BY) independently screened title, abstract and full text of 
relevant articles for inclusion. All disagreements were adjudicated by a third investigator 
(TN or CHTY). Authors of abstracts were contacted by email if necessary, to retrieve full 
text articles. Electronic data extraction forms were developed and pilot tested. Data 
extraction was independently performed by two investigators (SM and BY), and all 
discrepancies were adjudicated by a third investigator (TN or CHTY).
Assessment of study quality
Two investigators (CHTY and NS) independently assessed the risk of bias for each study 
using the ACRO-BAT-NRSI tool [13]. Using the GRADE (Grading of Recommendations, 
Assessment, Development and Evaluation) approach, two investigators (MP and AI) 
evaluated the quality/certainty of the evidence for each outcome, and a third investigator 
resolved any discrepancies (NS or CHTY) [14]. The quality of the evidence was assessed as 
high, moderate, low or very low. The effect estimates and quality of evidence were 
summarized in a GRADE evidence profile [15,16].
Statistical analysis
Analysis was conducted using RevMan 5.3 (RevMan, Computer Program, Copenhagen: The 
Nordic Cochrane Center, The Cochrane Collaboration, 2012) [17]. Results are expressed as 
risk ratios (RR) or mean differences (MD) with corresponding 95% confidence intervals 
(95% CI), or are presented narratively. For studies that described a single model of care, 
either the risk of an event (or proportion) was calculated, or the mean (or median) and 
standard deviation of the outcome point estimate were obtained.
It was determined a priori that a meta-analysis would be performed when estimates were 
clinically and statistically sufficiently homogenous. The intent was to conduct subgroup 
analyses by disease severity (severe: factor levels <1%; and non-severe: factor levels ≥1%), 
carriers of haemophilia, comorbidities (HIV, hepatitis), differing access to care (i.e. urban vs. 
rural) and age (paediatric: ≤18 years of age; older population: ≥65 years of age).
Results
The literature search identified 6789 non-duplicate records. After title and abstract 
screening, 197 articles were assessed for eligibility with full-text review, and subsequently, 
172 articles were excluded. Seven additional articles eligible for inclusion were retrieved 
during the process. As a result, 27 unique non-randomized studies (which were reported in 
32 published articles) were included. A PRISMA diagram of the selection flow is provided 
in Fig. 1. Eight studies were comparative and 19 studies were single-arm non-comparative 
studies.
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Characteristics of the included comparative and non-comparative studies are described in 
Table 1 and Appendix S2 respectively. The risk of bias of the comparative studies assessed 
using the ACROBAT-NRSI tool is presented in Table 2. We present a summary of the results 
from comparative studies in Table 3, and present the data from the non-comparative studies 
in Appendix S3. We reported the results with a study estimate or narrative, and did not 
perform a formal meta-analysis due to heterogeneity in the study designs and outcome 
definitions.
Mortality
One comparative non-randomized study by Soucie et al. [18] with 2950 participants, 
reported results on adjusted mortality over a three-year period. The risk of death was 
reduced in PWH receiving care at a Haemophilia Treatment Center (HTC) compared to not 
receiving care at an HTC (RR 0.60; 95% CI, 0.50–0.80), with an absolute overall death rate 
of 40.4 deaths/1000 person-years, reflective of the burden of HIV mortality [18]. Six unique 
non-comparative studies (which were reported in seven published articles) reported mortality 
as an event rate [19–25]. The number of deaths in the study population over 1–8 years, 
ranged from 6 to 100 deaths per 1000 persons (Appendix S3). Overall, the quality of 
evidence for a reduction in mortality with integrated care was low based on data from the 
non-randomized comparative study.
Missed days of school or work
Three studies measured days lost from work or school. Two before–after studies measured 
the mean number of days missed prior to and after implementation of an HTC (Table 3). 
Lazerson [26] with 20 patients before and after the implementation of integrated care, found 
a reduction in days [MD −50.20 (95% CI, −61.68, −38.72) days per year]. Smith and Levine 
[27] with 2112 participants before and 4742 after the adoption of integrated care, found a 
reduction of 10.2 days per year. The third study [28] compared participants with >11 days 
lost from work who had frequent HTC use to infrequent or first time use. We reanalyzed the 
data from 6420 participants and found a risk ratio of 1.01 (95% CI, 0.75–1.36) (Table 3). 
Seven unique non-comparative studies (which were reported in twelve published articles) 
reported a range of results with some reporting low rates in absenteeism, but others reporting 
greater than 15 missed days per year [22–24,29–37] (Appendix S3). Overall, there was very 
low-quality evidence for a reduction in missed days of work or school per year of 
approximately 10 days. This was primarily due to lack of adjustment for confounding factors 
in the comparative studies from Smith and Levine [27] and our reanalysis of Monahan et al. 
[28], and to the potential for little to no difference in days missed (Table 3).
Emergency room visits
Two comparative non-randomized studies measured the number of emergency room visits or 
hospitalizations. Soucie et al. [38] with 2546 participants, described the number of people 
with at least one hospitalization over 4 years. They reported that PWH who had received 
care at an HTC any time during the study period were hospitalized less than those who did 
not receive care at an HTC [RR 0.60 (95% CI, 0.50–0.70)] (Table 3). In agreement with 
Soucie et al. [38], a small study by Smith, Keyes and Forman [39] of 43 participants before 
and 23 participants after the implementation of integrated care, reported a mean difference 
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of 23.3 emergency room and walk-in clinic visits favouring integrated care (Table 2). Three 
non-comparative studies reported the mean number of emergency room visits [32,33,40] and 
ranged from 0.9 to 500 per 1000 persons per year (Appendix S3). Overall, the quality of 
evidence from the non-randomized comparative studies was low, although we did not 
downgrade for indirectness based on the use of hospitalizations to represent emergency 
room visits (Table 3).
Length of in-patient stay
One comparative non-randomized study by Smith and Levine [27] of 2112 participants 
before and 4742 participation after the adoption of integrated care, reported number of days 
spent in hospital. The mean difference in length of stay after implementation of integrated 
care was −7.6 days spent in the hospital per year (95% CI not reported) (Table 3). Thirteen 
non-comparative studies reported the mean number of days per patient per year [20–
24,34,35,40–45]. The mean number of visits ranged from 0.4 to 14.5 per person per year 
(Appendix S3). Overall, the quality of evidence was very low from the non-randomized 
comparative study which had a high risk of bias due to non-adjustment for potential 
confounding and potential bias from patients lost to follow-up and non-participation. These 
factors were considered with indirectness (study was from the 1980s and current treatment 
modalities have changed) and the few hospitalizations that occurred (Table 3).
Joint damage or disease (and other measures of functional status)
Two comparative non-randomized studies reported on the progression of joint damage or 
decreased activity (another measure of functional status) per year. Soucie et al. [46] with 
4343 participants, found that for PWH with severe disease, frequent HTC users (one or more 
visits per year) had less ROM limitation than infrequent users (less than one visit per year). 
In contrast, for PWH with moderate and mild disease, frequent HTC use was associated with 
higher ROM limitation, even when the association was tested in a model adjusted for age 
and BMI. The authors appropriately suggest that for mild and moderate patients, frequent 
bleeds may drive both frequency of HTC visits and limitation in ROM, creating a spurious 
(confounded) association (Table 3). From Monahan et al. [28], we reanalyzed the data from 
6420 participants to compare participants with decreased activity (actions related to work, 
school, recreation and self-care) who had frequent HTC use to infrequent or first time use 
and calculated RR 1.20 (95% CI, 0.98–1.46). Two unique non-comparative studies (which 
were reported in three published articles) reported [25,29,30] a range from 234 to 333 joints 
damaged or diseased per 1000 persons (Appendix S3). Four non-comparative studies (which 
were reported in six published articles) reported [23,24,31,36,37,47] that the proportion of 
patients with joint damage or disease ranged from 44 to 429 per 1000 persons (Appendix 
S3). Overall, there was very low-quality evidence for a reduction in joint damage or disease 
from the two comparative studies due to lack of adjustment for confounding factors in 
combination with indirectness (using decreased activity per year to define joint damage or 
disease) (Table 3).
Patient knowledge
The comparative non-randomized study by Arnold et al. [48] of 104 participants found that 
HTC attendance within the past 12 months was significantly associated (P < 0.05) with 
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increased knowledge seeking (e.g. recognizing and treating a bleed, knowledge of the 
genetics of haemophilia, physical activity selections) in an unadjusted analysis (Table 3). 
The overall quality of evidence was very low due to potential bias from unadjusted 
confounding factors, indirectness from defining integrated care as attendance at an HTC in 
the last 12 months, and few participants (Table 3).
Other outcomes
We did not find comparative studies reporting on quality of life, educational attainment and 
patient adherence. However, two non-comparative studies reported that 83–494 per 1000 
persons adhered to their treatment regimens [31,49] (Appendix S3).
Discussion
We found low- to very low-quality evidence that integrated care reduces mortality, 
emergency room and walk-in clinic visits, hospitalizations (and length of stay), missed days 
of school and work, and increases knowledge seeking. The evidence for the effects of 
integrated care on functional status, measured by joint damage or joint disease was less 
clear, and the analysis is likely confounded by disease severity. This means that the true 
effects of integrated care may be substantially different from what we found (i.e. 
overestimated or under-estimated). We also did not find evidence to compare the effects of 
integrated care to other models for quality of life, educational attainment and patient 
adherence.
This systematic review has two clear strengths: its rigorous methodology and its 
comprehensive scope. Our systematic search of electronic databases was supplemented with 
snowballing and broad expert consultation (useful strategies when addressing a rare disease). 
We did not restrict by study design and therefore believe that we have captured the current 
available evidence for care models in PWH. We used best-in-class tools to assess risk of bias 
and evaluate the quality of the body of evidence to interpret and present the current best 
evidence. Despite the comprehensive search, we found few comparative studies yielding a 
limited body of evidence, but allowing us to suggest several considerations for future 
research.
Limitations of the current body of evidence clearly indicate targets for improvement. The 
conduct of randomized controlled trials in health care services and different care models is 
possible but very challenging, as evident from systematic reviews of randomized controlled 
trials of health care models in other chronic conditions, such as asthma and chronic 
obstructive pulmonary disease [50–53]. The challenges would be even greater in 
haemophilia, where the rarity of disease, the long-term nature of the most patient-important 
outcomes (e.g. mortality or joint disease), and the widespread adoption of the integrated care 
model as standard of care would make a randomized trial almost impossible to perform. 
However, even where integrated care models are already in place, non-randomized studies 
comparing PWH attending integrated or non-integrated care are still feasible.
First, future attempts to more clearly define integrated and non-integrated care groups could 
be made. We found three studies by Soucie et al. [18,38,46] and another by Monahan et al. 
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[28] that included large populations of PWH and compared the risk of many important 
patient outcomes between different uses of HTC and integrated care. Use and attendance at 
HTC were however, defined differently across these studies. Soucie et al. [18,38] defined 
their integrated and non-integrated care arms as patients attending HTC and non-HTC 
respectively. In contrast, the other studies did not define integrated and non-integrated care 
arms, and thus we reanalyzed their data to provide comparisons. Soucie et al. [46] and 
Monahan et al. [28] compared the frequency of HTC visits rather than HTC and non-HTC 
arms. To reanalyzed this data, we defined integrated care as equivalent to frequent HTC use 
(one or more visits per year) and non-integrated care as equivalent to infrequent HTC use 
(less than one visit per year) or first time visits. These were, admittedly, indirect measures of 
integrated and non-integrated care. Stemming from the literature we reviewed, integrated 
care would include supervision of the PWH by a coordinated and centralized 
multidisciplinary team. The integrated care model would include some or all of the 
following: provide home-based treatment, coordinated care and technical assistance; secure 
and administer funding; organize professional education and training; and engage in data 
collection and analysis. Therefore, in future studies, it will be important to provide details on 
which components and functions the specific integrated care model under study entails. The 
non-integrated care group would be further defined as the specialist-based care model that 
centres on a haematologist, who may or may not have specialized training in haemophilia, 
providing care in a non-specialized centre, such as a hospital or medical office; care 
delivered by a non-specialist in a non-specialist setting with a family physician delivering 
care in their practice, or an emergency room physician delivering care in a hospital; or the 
‘no care’ model, in which there is a complete absence of care. Of course, integrated care 
models with different compositions or function could also be used as comparators.
Second, we found that the selected outcomes, and how they were defined and measured 
were very heterogeneous across studies, which essentially prevented us from pooling data 
across studies. Few to no studies reported on some of our set of outcomes, which were 
identified as important by key stakeholders [12]. Additionally, reported outcomes were 
measured differently from study to study. For example, missed days of school or work was 
measured continuously in days in some studies, but dichotomized as the number of people 
who had greater or less than a threshold value of missed days in others. In future research, 
we suggest that data should be collected and analyzed for standardized measures of missed 
days from work or school, length of in-patient stay, quality of life, joint damage and other 
functional outcomes, educational attainment, patient adherence, and patient knowledge. 
Reference to standardized international definitions can be of value [54].
Third, we had hypothesized that integrated care may have different effects in different 
populations with haemophilia, but we were unable to incorporate subgroup analyses into this 
review. There were a paucity of data from the studies to group by disease severity, age (in 
particular paediatric and geriatric groups), inhibitor status, ethnicity, comorbidities and 
access to care (i.e. insurance status). We found one large study showing that effects on joint 
damage or disease may be related to severity of haemophilia, but were unable to explore this 
further in other studies. In the future, studies addressing these principle subgroups would 
allow for analyses to determine the benefits or harms of integrated care models in specific 
populations.
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Conclusions
To the best of our knowledge, this is the first systematic review to assess the impact of 
models of care delivery on important outcomes for patients with haemophilia. From its 
results, it is clear that care models in the management of haemophilia is a research topic that 
has been relatively neglected in the past, which is likely amplified by the rare disease setting. 
While the paucity of supportive evidence has not had a negative impact on the provision of 
integrated care, it should be noted that, at least in the US, approximately two-thirds of the 
haemophilia population receive care from an HTC [18], a figure that is certainly much lower 
in developing countries. Should further research reinforce integrated care as an important 
component of haemophilia management on patient-important outcomes, there may be 
important implications for future research to address and overcome barriers to HTC 
utilization, including the allocation of resources to areas that need this care. On the other 
hand, if further research changes the current favourable effects of integrated care, then it 
may be worth considering providing less costly and resource-intensive care models to 
specific patient populations, perhaps starting with those with low disease burden. 
Coordinated, well-funded, large-scale research initiatives to better understand the effect of 
care models in the management of haemophilia are worth being pursued and are urgently 
needed. On this note, this review provides a starting point and many suggestions for future 
research on integrated health care models in PWH.
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Fig. 1. 
PRISMA flow diagram for care models in the management of haemophilia.
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